Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling-Reference-Cited by-同舟云学术

Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling

Published:2013-07-02 Issue:12 Volume:52 Page:1085-1100
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Barter Zoe E.,Tucker Geoffrey T.,Rowland-Yeo Karen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-013-0089-y.pdf

Reference76 articles.

1. Kudrin A. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia. J Clin Pharmacol. 2009;49(3):268–80.

2. Emerging pharmaceutical market in China—forecast to become the world’s third-largest pharmaceutical market by 2013. http://www.marketresearch.com/GBI-Research-v3759/Emerging-Pharmaceutical-China-Forecast-Largest-6564799/ . Accessed 23 May 2013.

3. Malinowski HJ, Westelinck A, Sato J, Ong T. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan. J Clin Pharmacol. 2008;48(8):900–8.

4. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov. 2007;6(2):140–8.

5. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into pharmacogenetics, drug-gene interactions, and drug-drug-gene interactions;Drug Metabolism Reviews;2024-08-18

2. Establishing Virtual Bioequivalence and Clinically Relevant Specifications for Omeprazole Enteric-Coated Capsules by Incorporating Dissolution Data in PBPK Modeling;The AAPS Journal;2024-07-12

3. Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug–drug Interactions;Clinical Pharmacokinetics;2024-05-31

4. Model informed drug development: HSK21542 PBPK model supporting dose decisions in specific populations;European Journal of Pharmaceutical Sciences;2024-05

5. Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach;Frontiers in Pharmacology;2024-03-04